Aspire Biopharma, Inc. Continues to Build a World Class Team

HUMACAO, PR, May 17, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of Nancy Taylor, Esq., to its highly skilled team of professional advisors.

Aspire Biopharma, Inc. is excited to announce securing an engagement with Nancy Taylor, Esq., the Chair of the Health Care and FDA Practice at Greenberg Traurig, LLP.  Ms. Taylor brings broad experience working with providers, plans, employers, private equity firms, and FDA-regulated companies. The full biographical information on each of the Aspire team members can be found on the Company’s website in the investor relations section:

Kraig Higginson, Executive Chairman, stated, “We are extremely excited to have the opportunity to have Nancy Taylor on our team to advise us through our pursuit of taking our launch product, Instaprin, through the FDA 505(b)(2) Fast Track process.”

About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit

Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward- looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.